Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aprea Therapeutics, Inc. - Common Stock (NQ:APRE)

0.8775 -0.1025 (-10.46%)
Streaming Delayed Price Updated: 2:39 PM EDT, Aug 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,032,911
Open 0.9900
Bid (Size) 0.8550 (300)
Ask (Size) 0.9000 (300)
Prev. Close 0.9800
Today's Range 0.8100 - 0.9900
52wk Range 0.5480 - 1.690
Shares Outstanding 5,979,292
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
Unusual volume stocks in Wednesday's session ↗
Via Chartmill

Performance

YTD
+2.9%
+2.9%
1 Month
+40.5%
+40.5%
3 Month
-4.1%
-4.1%
6 Month
+0.3%
+0.3%
1 Year
-44.5%
-44.5%

More News

Read More
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
News headline image
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics (NASDAQ:APRE) Q1 2026 Results: Clinical Progress Drives Stock Higher ↗
Via Chartmill
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Targets Next Wave of DNA Damage Response Cancer Therapies
Via Investor Brand Network
Topics Artificial Intelligence
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
Via Investor Brand Network
News headline image
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial
From Aprea Therapeutics
Via GlobeNewswire
Gapping stocks in Monday's session ↗
Via Chartmill
News headline image
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial ↗
Via Stocktwits
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
From Aprea Therapeutics
Via GlobeNewswire
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Check out the stocks that are attracting the most attention and driving market activity. ↗
Via Chartmill
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill

Frequently Asked Questions

Is Aprea Therapeutics, Inc. - Common Stock publicly traded?
Yes, Aprea Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Aprea Therapeutics, Inc. - Common Stock trade on?
Aprea Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aprea Therapeutics, Inc. - Common Stock?
The ticker symbol for Aprea Therapeutics, Inc. - Common Stock is APRE on the Nasdaq Stock Market
What is the current price of Aprea Therapeutics, Inc. - Common Stock?
The current price of Aprea Therapeutics, Inc. - Common Stock is 0.8775
When was Aprea Therapeutics, Inc. - Common Stock last traded?
The last trade of Aprea Therapeutics, Inc. - Common Stock was at 08/27/26 02:39 PM ET
What is the market capitalization of Aprea Therapeutics, Inc. - Common Stock?
The market capitalization of Aprea Therapeutics, Inc. - Common Stock is 5.25M
How many shares of Aprea Therapeutics, Inc. - Common Stock are outstanding?
Aprea Therapeutics, Inc. - Common Stock has 5M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.